The Journal of Urology
Volume 180, Issue 3 , Pages 806-807 , September 2008

RUNX3 Methylation and the Potential to Predict the Behavior of Bladder Cancer

References 

  1. Zhang Z, Karam J, Frenkel E, Sagalowsky A, Hsieh JT. The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol Oncol. 2006;24:152
  2. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome — components and functional correlates. Genes Dev. 2006;20:3215
  3. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs. 2007;16:659
  4. Moore LE, Pfeiffer RM, Poscablo C, Real FX, Kogevinas M, Silverman D, et al. Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol. 2008;9:359
  5. Tada Y, Yokomizo A, Kuroiwa K, Tsunoda T, Uchino H, Plass C, et al. The association of TLX3 methylation with resistance to cisplatin in bladder cancer. J Urol. 2008;179:372
  6. Ellinger J, El Kassem N, Heukamp LC, Mathews S, Cubuklouz F, Kahl P, et al. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J Urol. 2008;179:346
  7. Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, Li QL, et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res. 2005;65:9347
  8. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002;109:113
  9. Ito Y. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res. 2008;99:33

PII: S0022-5347(08)01702-3

doi: 10.1016/j.juro.2008.06.073

The Journal of Urology
Volume 180, Issue 3 , Pages 806-807 , September 2008

Article Tools